Garai, Pratik and Chakraborty, Arindam and Banerjee, Madhumita and Mukherjee, Payel (2024) A Comprehensive Review on Biosimilars: Present & Future. Journal of Pharmaceutical Research International, 36 (12). pp. 198-205. ISSN 2456-9119
Chakraborty36122024JPRI128495.pdf - Published Version
Download (384kB)
Abstract
For providing treatment about most complex disease like cancer, hormone inadequacy, kidney problems, life-threatening and many types of rare illnesses biologics are conducting a major role of the biopharmaceutical market. But there are many problems faces that’s are a highly complex process, patent expires, cost effective etc. for those type of reason and more patient demand a similar drug is making which is as similar as biologics drug, simple making process, and less costly. A biologic is a medicine that is biosimilar medical product which is subsequently adaptation of the biologic product or almost an identical substitute of the original product which is manufactured by other brand of company. Although biosimilar drug has FDA approved for manufacturing but they also have to require a different approval for those drug marketing, since they are the reason why they are not a generic form of biologics. Biosimilar drug are not exact copy the originator drug, they are similarly designed the innovator drug. This paper mainly highlighted to the current scenario of biosimilar drug in biopharmaceutical field also the future result of this similar biologic drug in biopharmaceutical field. Biosimilars are hardly offer to promising that it was a beneficial and less cost-effective site for patient and doctors also.
Item Type: | Article |
---|---|
Subjects: | Open Asian Library > Medical Science |
Depositing User: | Unnamed user with email support@openasianlibrary.com |
Date Deposited: | 11 Jan 2025 05:13 |
Last Modified: | 11 Jan 2025 05:13 |
URI: | http://journal.eprintjournalhub.in/id/eprint/1926 |